CeriBell (NASDAQ:CBLL) Trading Up 5.7% – What’s Next?

CeriBell (NASDAQ:CBLL)’s share price traded up 5.7% during mid-day trading on Friday . The company traded as high as $24.35 and last traded at $24.42. 92,156 shares changed hands during mid-day trading, a decline of 45% from the average session volume of 166,898 shares. The stock had previously closed at $23.11.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the stock. JPMorgan Chase & Co. assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “overweight” rating and a $32.00 price target on the stock. William Blair assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued an “outperform” rating on the stock. Canaccord Genuity Group assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $30.00 price target on the stock. TD Cowen increased their price target on shares of CeriBell from $31.00 to $36.00 and gave the stock a “buy” rating in a report on Monday, December 9th. Finally, Bank of America assumed coverage on shares of CeriBell in a report on Tuesday, November 5th. They issued a “buy” rating and a $32.00 price target on the stock. Six equities research analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and an average target price of $32.60.

CeriBell Trading Up 6.8 %

The stock’s 50-day moving average is $23.53.

Institutional Investors Weigh In On CeriBell

Several hedge funds have recently bought and sold shares of CBLL. Rhumbline Advisers bought a new stake in CeriBell during the fourth quarter valued at approximately $320,000. Bank of New York Mellon Corp bought a new stake in shares of CeriBell in the 4th quarter worth approximately $628,000. Charles Schwab Investment Management Inc. bought a new stake in shares of CeriBell in the 4th quarter worth approximately $2,500,000. PNC Financial Services Group Inc. bought a new stake in shares of CeriBell in the 4th quarter worth approximately $47,000. Finally, Vanguard Group Inc. bought a new stake in shares of CeriBell in the 4th quarter worth approximately $18,015,000.

CeriBell Company Profile

We are a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. We have developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting.